Mesoblast Limited (MESO) PT Set at $14.00 by Maxim Group
Mesoblast Limited (NASDAQ:MESO) has been given a $14.00 target price by equities research analysts at Maxim Group in a research report issued to clients and investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 93.91% from the stock’s previous close.
Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Mesoblast Limited from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. BidaskClub lowered shares of Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Credit Suisse Group set a $11.00 price objective on shares of Mesoblast Limited and gave the company a “hold” rating in a research note on Tuesday, July 18th. Finally, Cantor Fitzgerald began coverage on shares of Mesoblast Limited in a research note on Wednesday, June 7th. They issued a “buy” rating and a $20.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Mesoblast Limited has a consensus rating of “Hold” and a consensus target price of $12.70.
Shares of Mesoblast Limited (MESO) traded up 3.29% during midday trading on Wednesday, reaching $7.22. 20,351 shares of the company’s stock traded hands. The stock has a 50 day moving average of $7.42 and a 200-day moving average of $8.21. The stock’s market cap is $574.31 million. Mesoblast Limited has a 12 month low of $4.01 and a 12 month high of $12.50.
An institutional investor recently raised its position in Mesoblast Limited stock. Princeton Capital Management Inc. boosted its position in shares of Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned 0.20% of Mesoblast Limited worth $1,398,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.92% of the company’s stock.
Mesoblast Limited Company Profile
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.